113 related articles for article (PubMed ID: 7728149)
1. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection.
Krawczak M; Smith-Sorensen B; Schmidtke J; Kakkar VV; Cooper DN; Hovig E
Hum Mutat; 1995; 5(1):48-57. PubMed ID: 7728149
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area.
Eachkoti R; Hussain I; Afroze D; Aejazaziz S; Jan M; Shah ZA; Das BC; Siddiqi MA
Cancer Lett; 2007 Apr; 248(2):308-20. PubMed ID: 16996204
[TBL] [Abstract][Full Text] [Related]
3. TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.
de Anta JM; Jassem E; Rosell R; Martínez-Roca M; Jassem J; Martínez-López E; Monzó M; Sánchez-Hernández JJ; Moreno I; Sánchez-Céspedes M
Oncogene; 1997 Dec; 15(24):2951-8. PubMed ID: 9416838
[TBL] [Abstract][Full Text] [Related]
4. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
5. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
[TBL] [Abstract][Full Text] [Related]
6. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
7. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier M; Hussain SP; Caron de Fromentel C; Hainaut P; Harris CC
IARC Sci Publ; 2004; (157):247-70. PubMed ID: 15055300
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
11. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in XPD and TP53 and mutation in human lung cancer.
Mechanic LE; Marrogi AJ; Welsh JA; Bowman ED; Khan MA; Enewold L; Zheng YL; Chanock S; Shields PG; Harris CC
Carcinogenesis; 2005 Mar; 26(3):597-604. PubMed ID: 15564288
[TBL] [Abstract][Full Text] [Related]
13. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
14. Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs).
Upadhyaya M; Kluwe L; Spurlock G; Monem B; Majounie E; Mantripragada K; Ruggieri M; Chuzhanova N; Evans DG; Ferner R; Thomas N; Guha A; Mautner V
Hum Mutat; 2008 Jan; 29(1):74-82. PubMed ID: 17960768
[TBL] [Abstract][Full Text] [Related]
15. Comparison of induced and cancer-associated mutational spectra using multivariate data analysis.
Lewis PD; Manshian B; Routledge MN; Scott GB; Burns PA
Carcinogenesis; 2008 Apr; 29(4):772-8. PubMed ID: 18296683
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives.
de Moura Gallo CV; Azevedo E Silva Mendonça G; de Moraes E; Olivier M; Hainaut P
Mutat Res; 2005 May; 589(3):192-207. PubMed ID: 15878142
[TBL] [Abstract][Full Text] [Related]
17. High sensitivity of detection of TP53 somatic mutations by fluorescence-assisted mismatch analysis.
Tessitore A; Di Rocco ZC; Cannita K; Ricevuto E; Toniato E; Tosi M; Ficorella C; Frati L; Gulino A; Marchetti P; Martinotti S
Genes Chromosomes Cancer; 2002 Sep; 35(1):86-91. PubMed ID: 12203794
[TBL] [Abstract][Full Text] [Related]
18. Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas.
van Wyk R; Slezak P; Hayes VM; Buys CH; Kotze MJ; de Jong G; Rubio C; Dolk A; Jaramillo E; Koizumi K; Grobbelaar JJ
Genes Chromosomes Cancer; 2000 Feb; 27(2):202-8. PubMed ID: 10612810
[TBL] [Abstract][Full Text] [Related]
19. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K; Rannala B; Traisathit P; Srikummool M; Wongchai Y; Kangwanpong D
Cancer Genet Cytogenet; 2008 Aug; 185(1):20-7. PubMed ID: 18656689
[TBL] [Abstract][Full Text] [Related]
20. Mutational inactivation of the nijmegen breakage syndrome gene (NBS1) in glioblastomas is associated with multiple TP53 mutations.
Watanabe T; Nobusawa S; Lu S; Huang J; Mittelbronn M; Ohgaki H
J Neuropathol Exp Neurol; 2009 Feb; 68(2):210-5. PubMed ID: 19151620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
